Mirtazapin Actavis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Actavis, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an unspecified strength tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Actavis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used primarily in the management of depressive disorders.

Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. Depressive episodes in bipolar I disorder (as adjunct): helps manage the depressive phase when combined with mood stabilisers. Depression with prominent insomnia: provides a sedative effect that can improve sleep quality while treating depression.

Common Side Effects: - Sedation or drowsiness - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness or light‑headedness - Blurred vision

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Emergence of suicidal thoughts, especially early in treatment - Severe hypersensitivity reactions (rash, angioedema) - Hepatic dysfunction or jaundice

Before initiating therapy, consider the following precautions: - Assess hepatic function: adjust use in severe liver impairment. - Monitor weight and appetite: risk of significant weight gain. - Evaluate for suicidal ideation: especially during the first weeks. - Avoid abrupt discontinuation: taper to prevent withdrawal symptoms. - Caution in cardiovascular disease: may cause orthostatic hypotension. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Mirtazapin Actavis may interact with several medicines.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., alcohol, benzodiazepines): additive sedation. - Other serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase mirtazapine levels. - CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy.